Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4498) 4498
Book Review (879) 879
Publication (236) 236
Magazine Article (54) 54
Book Chapter (33) 33
Book / eBook (32) 32
Conference Proceeding (5) 5
Trade Publication Article (5) 5
Government Document (4) 4
Web Resource (4) 4
Dissertation (2) 2
Paper (1) 1
Presentation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3942) 3942
humans (3141) 3141
antidotes - therapeutic use (2766) 2766
male (1747) 1747
animals (1553) 1553
female (1277) 1277
toxicology (987) 987
antidotes (969) 969
adult (881) 881
poisoning (674) 674
pharmacology & pharmacy (668) 668
abridged index medicus (648) 648
antidotes - administration & dosage (620) 620
middle aged (599) 599
rats (592) 592
poisoning - drug therapy (563) 563
mice (478) 478
antidote (469) 469
antidotes - pharmacology (461) 461
toxicity (451) 451
poisoning - therapy (408) 408
aged (394) 394
treatment outcome (367) 367
adolescent (343) 343
time factors (332) 332
child (323) 323
overdose (315) 315
care and treatment (311) 311
health aspects (304) 304
charcoal - therapeutic use (279) 279
dose-response relationship, drug (253) 253
child, preschool (249) 249
emergency medicine (248) 248
intoxication (240) 240
administration, oral (234) 234
medicine, general & internal (231) 231
acute disease (221) 221
atropine - therapeutic use (220) 220
drug overdose (219) 219
drugs (217) 217
antidotes - adverse effects (216) 216
acetaminophen - poisoning (207) 207
analysis (199) 199
retrospective studies (191) 191
cyanides - poisoning (188) 188
poisoning - diagnosis (188) 188
management (186) 186
acetylcysteine - therapeutic use (184) 184
organophosphate poisoning (179) 179
therapy (178) 178
drug therapy, combination (177) 177
oncology (174) 174
research (174) 174
rats, wistar (170) 170
pharmacokinetics (169) 169
dosage and administration (166) 166
risk factors (166) 166
suicide, attempted (162) 162
oximes (161) 161
pralidoxime compounds - therapeutic use (161) 161
gastric lavage (160) 160
infant (159) 159
insecticides - poisoning (159) 159
drug overdose - drug therapy (158) 158
efficacy (154) 154
pyrazoles - therapeutic use (153) 153
usage (151) 151
acetylcholinesterase (143) 143
anticoagulants (143) 143
dogs (143) 143
cholinesterase reactivators - therapeutic use (140) 140
lethal dose 50 (140) 140
organophosphorus compounds (140) 140
thiosulfates - therapeutic use (139) 139
pharmacology/toxicology (138) 138
young adult (137) 137
drug therapy (135) 135
infusions, intravenous (132) 132
leucovorin - therapeutic use (132) 132
complications and side effects (131) 131
pediatrics (128) 128
emergency (125) 125
flumazenil - therapeutic use (125) 125
aged, 80 and over (124) 124
anticoagulants - adverse effects (124) 124
acetaminophen (123) 123
dabigatran (123) 123
injections, intravenous (123) 123
antidotes - chemistry (122) 122
chelating agents - therapeutic use (122) 122
renal dialysis (122) 122
disease models, animal (121) 121
hemorrhage - chemically induced (121) 121
oximes - therapeutic use (121) 121
antidotes - pharmacokinetics (119) 119
biochemistry & molecular biology (119) 119
nursing (119) 119
prospective studies (119) 119
biomedicine (118) 118
chemical warfare agents - poisoning (118) 118
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (18) 18
Online Resources - Online (5) 5
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Humber River Regional Hospital - Church Stacks (2) 2
Scarborough Hospital - Birchmount (2) 2
Scarborough Hospital - General (2) 2
UofT at Mississauga - Stacks (2) 2
Earth Sciences (Noranda) - Stacks (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Pharmacy (1) 1
Pontifical Inst. Mediaeval Studies - Library use only (1) 1
Royal Ontario Museum - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
Thomas Fisher Rare Book - Rare Book (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3861) 3861
German (200) 200
Russian (191) 191
French (86) 86
Spanish (50) 50
Japanese (31) 31
Chinese (30) 30
Polish (25) 25
Danish (19) 19
Swedish (18) 18
Czech (14) 14
Hungarian (14) 14
Dutch (12) 12
Italian (12) 12
Bulgarian (11) 11
Finnish (10) 10
Serbian (9) 9
Hebrew (5) 5
Norwegian (5) 5
Romanian (5) 5
Croatian (4) 4
Portuguese (2) 2
Turkish (2) 2
Ukrainian (2) 2
Arabic (1) 1
Bosnian (1) 1
Icelandic (1) 1
Judeo-Arabic (1) 1
Korean (1) 1
Latin (1) 1
Lithuanian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
by Siegal, Deborah M and Curnutte, John T and Connolly, Stuart J and Lu, Genmin and Conley, Pamela B and Wiens, Brian L and Mathur, Vandana S and Castillo, Janice and Bronson, Michele D and Leeds, Janet M and Mar, Florie A and Gold, Alex and Crowther, Mark A
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 25, pp. 2413 - 2424
The new oral anticoagulants have many advantages over warfarin, but one disadvantage is the inability to rapidly reverse their anticoagulant effects.... 
MEDICINE, GENERAL & INTERNAL | MANAGEMENT | APIXABAN | WARFARIN | ATRIAL-FIBRILLATION | Recombinant Proteins - therapeutic use | Pyrazoles - therapeutic use | Humans | Middle Aged | Male | Rivaroxaban - adverse effects | Female | Factor Xa - therapeutic use | Prothrombin - metabolism | Rivaroxaban - therapeutic use | Pyrazoles - adverse effects | Antidotes - pharmacology | Peptide Fragments - metabolism | Double-Blind Method | Administration, Oral | Recombinant Proteins - pharmacology | Factor Xa - metabolism | Protein Precursors - metabolism | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Blood Coagulation - drug effects | Factor Xa - pharmacology | Factor Xa Inhibitors - adverse effects | Aged | Pyridones - therapeutic use | Hemorrhage - chemically induced | Pyridones - adverse effects | Antidotes - therapeutic use | Treatment outcome | Usage | Analysis | Clinical trials | Anticoagulants (Medicine) | Dosage and administration | Hemorrhage | Risk factors | Prevention | Anticoagulants | Side effects | Inhibitor drugs | Prothrombin | Thrombin | Thrombosis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting With Major Bleeding: A Randomized, Plasma-Controlled, Phase IIIb Study
by Sarode, Ravi and Milling, Truman J and Refaai, Majed A and Mangione, Antoinette and Schneider, Astrid and Durn, Billie L and Goldstein, Joshua N
Circulation, ISSN 0009-7322, 09/2013, Volume 128, Issue 11, pp. 1234 - 1243
BACKGROUND—Patients experiencing major bleeding while taking vitamin K antagonists require rapid vitamin K antagonist reversal. We performed a prospective... 
CARDIAC & CARDIOVASCULAR SYSTEMS | ORAL ANTICOAGULANT REVERSAL | CLINICAL-TRIAL | RECOMBINANT FACTOR-VIII | vitamin K antagonist | prothrombin complex concentrates | PREVIOUSLY UNTREATED PATIENTS | INTRACRANIAL HEMORRHAGE | THERAPY | WARFARIN | TRANSFUSION | HEMOPHILIA-A | anticoagulants | PERIPHERAL VASCULAR DISEASE | plasma | FRESH-FROZEN PLASMA | hemorrhage | Single-Blind Method | Plasma | Prospective Studies | Thromboembolism - chemically induced | Factor IX - therapeutic use | Humans | Middle Aged | Male | Factor IX - adverse effects | Hemorrhage - prevention & control | Vitamin K - antagonists & inhibitors | Thromboembolism - prevention & control | Aged, 80 and over | Adult | Factor X - therapeutic use | Female | Factor X - adverse effects | Factor VII - adverse effects | Factor VII - therapeutic use | Emergencies | Anticoagulants - therapeutic use | Treatment Outcome | Prothrombin - therapeutic use | Anticoagulants - adverse effects | Prothrombin - adverse effects | Hemostatics - adverse effects | International Normalized Ratio | Hemorrhage - drug therapy | Blood Coagulation Factors - adverse effects | Anticoagulants - pharmacology | Blood Coagulation Factors - therapeutic use | Aged | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Drug Combinations | Antidotes - therapeutic use | Antagonists (Biochemistry) | Usage | Care and treatment | Blood coagulation factors | Health aspects | Hemorrhage | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text The therapeutic use of localized cooling in the treatment of VX poisoning
by Sawyer, T.W and Mikler, J and Worek, F and Reiter, G and Thiermann, H and Tenn, C and Weatherby, K and Bohnert, S
Toxicology Letters, ISSN 0378-4274, 2011, Volume 204, Issue 1, pp. 52 - 56
► Topical exposure to the nerve agent VX was extremely toxic in an anaesthetized swine model. ► Oxime/atropine (pralidoxime or HI-6) treatment, or... 
Chemical Warfare (CW) | HI-6 | Decontamination | Reactive Skin Decontaminant Lotion ® (RSDL ®) | Hypothermia | VX | Reactive Skin Decontaminant Lotion | ) | RSDL | CHOLINESTERASE | VIVO | DOMESTIC SWINE | Reactive Skin Decontaminant Lotion (R) (RSDL (R)) | TEMPERATURE | TOKYO SUBWAY | SKIN ABSORPTION | JAPAN | SARIN | TOXICOLOGY | MUSTARD IN-VITRO | MATSUMOTO | Atropine - therapeutic use | Animals | Organothiophosphorus Compounds - blood | Time Factors | Swine | Chemical Warfare Agents - poisoning | Male | Organothiophosphorus Compounds - poisoning | Cryotherapy | Antidotes - therapeutic use | Nerve gas | Care and treatment | Poisoning | Health aspects | Analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Zinc, copper, or magnesium supplementation against cadmium toxicity
by Matović, Vesna, 1953
2010, Environmental science, engineering and technology series, ISBN 1616683325, xiv, 58
Cadmium | Antidotes | Zinc in the body | prevention & control | Zinc | Cadmium Poisoning | Copper in the body | Toxicology | adverse effects | Magnesium | Copper | therapeutic use | Magnesium in the body
Book
Details down arrow
5. On poisons and the protection against lethal drugs
: a parallel Arabic-English edition
by Maimonides, Moses, 1135-1204 and Bos, Gerrit, 1948 and McVaugh, M. R. 1938- (Michael Rogers)
2009, 1st ed., Medical works of Moses Maimonides, ISBN 9780842527309, 1 v. (various pagingings)
Poisons | Antidotes | Medicine, Arabic | Early works to 1800 | History, Medieval | history | therapeutic use | Medicine, Arab
Book
Details down arrow
6. Antidotes for poisoning by paracetamol
by Meredith, T. J. (Tim J.) and World Health Organization and International Program on Chemical Safety and Commission of the European Communities
1995, IPCS/EC evaluation of antidotes series, ISBN 0521495768, Volume 15693 EN, xiv, 95
Toxicology | Antidotes | poisoning | Acetaminophen | therapeutic use
Book
Details down arrow
7. Full Text Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran
by Pollack, Charles V and Reilly, Paul A and Bernstein, Richard and Dubiel, Robert and Eikelboom, John and Glund, Stephan and Huisman, Menno V and Hylek, Elaine and Kam, Chak-Wah and Kamphuisen, Pieter W and Kreuzer, Joerg and Levy, Jerrold H and Sellke, Frank and Stangier, Joachim and Steiner, Thorsten and Wang, Bushi and Weitz, Jeffrey I
Thrombosis and Haemostasis, ISSN 0340-6245, 07/2015, Volume 114, Issue 1, pp. 198 - 205
Idarucizumab, a Fab fragment directed against dabigatran, produced rapid and complete reversal of the anticoagulation effect of dabigatran in animals and in... 
Trial Protocol Design Paper | ANTIDOTE | STROKE | DIRECT THROMBIN INHIBITOR | MANAGEMENT | PHARMACOKINETICS | WARFARIN | RECOMMENDATIONS | CONCENTRATE BERIPLEX P/N | PERIPHERAL VASCULAR DISEASE | DIRECT ORAL ANTICOAGULANTS | OUTCOMES | HEMATOLOGY | Antibodies, Monoclonal, Humanized - adverse effects | Blood Loss, Surgical - prevention & control | Dabigatran - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Antithrombins - therapeutic use | Humans | Clinical Protocols | Treatment Outcome | Hemorrhage - prevention & control | Dabigatran - therapeutic use | Hemorrhage - diagnosis | Coagulants - therapeutic use | Blood Coagulation - drug effects | Antithrombins - adverse effects | Blood Coagulation Tests | Hemorrhage - chemically induced | Coagulants - adverse effects | Research Design
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Meta‐analysis of the efficacy and safety of new oral anticoagulants in patients with cancer‐associated acute venous thromboembolism
by Hulle, T and Exter, P. L and Kooiman, J and Hoeven, J. J. M and Huisman, M. V and Klok, F. A
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 07/2014, Volume 12, Issue 7, pp. 1116 - 1120
Introduction: Treatment of acute venous thromboembolism (VTE) in cancer patients is challenging, owing to a high risk of recurrent VTE and bleeding... 
anticoagulants | neoplasms | treatment outcome | venous thromboembolism | hemorrhage | Anticoagulants | Treatment outcome | Hemorrhage | Neoplasms | Venous thromboembolism | THROMBOSIS | RIVAROXABAN | PREVENTION | ANTIDOTE | DABIGATRAN | WARFARIN | MOLECULAR-WEIGHT HEPARIN | DISEASE | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | Recurrence | Thiophenes - therapeutic use | Acute Disease | Venous Thrombosis - drug therapy | Administration, Oral | Humans | Anticoagulants - therapeutic use | Risk | Treatment Outcome | Venous Thrombosis - complications | Heparin, Low-Molecular-Weight - therapeutic use | Randomized Controlled Trials as Topic | Neoplasms - complications | Rivaroxaban | Neoplasms - therapy | Morpholines - therapeutic use | Complications and side effects | Care and treatment | Cancer patients | Analysis | Anticoagulants (Medicine) | Thromboembolism | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Intravenous Thrombolysis With Recombinant Tissue-Type Plasminogen Activator in a Stroke Patient Receiving Dabigatran Anticoagulant After Antagonization With Idarucizumab
by Berrouschot, Jörg and Stoll, Anett and Hogh, Theresa and Eschenfelder, Christoph Cyrill
Stroke, ISSN 0039-2499, 07/2016, Volume 47, Issue 7, pp. 1936 - 1938
BACKGROUND AND PURPOSE—Therapeutic options for acute ischemic stroke patients presenting on effective anticoagulation are limited. Idarucizumab, a humanized,... 
anticoagulants | antidotes | dabigatran | idarucizumab | stroke | RATIONALE | GUIDELINES | HEALTH-CARE PROFESSIONALS | CLINICAL NEUROLOGY | REVERSAL | EARLY MANAGEMENT | ANTIDOTE | ACUTE ISCHEMIC-STROKE | PERIPHERAL VASCULAR DISEASE | Brain Ischemia - complications | Recombinant Proteins - therapeutic use | Severity of Illness Index | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Atrial Fibrillation - complications | Diabetes Mellitus, Type 2 - diet therapy | Male | Tissue Plasminogen Activator - administration & dosage | Tissue Plasminogen Activator - therapeutic use | Dabigatran - antagonists & inhibitors | Dabigatran - therapeutic use | Recombinant Proteins - administration & dosage | Recovery of Function | Thrombophilia - etiology | Brain Ischemia - drug therapy | Thrombolytic Therapy | Hypertension - complications | Aged | Infarction, Middle Cerebral Artery - etiology | Paresis - etiology | Diabetes Mellitus, Type 2 - complications | Thrombophilia - drug therapy | Antidotes - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate
by Zahir, Hamim and Zahir, Hamim and Brown, Karen S and Vandell, Alexander G and Desai, Madhuri and Maa, Jen-Fue and Dishy, Victor and Lomeli, Barbara and Feussner, Annette and Feng, Wenqin and He, Ling and Grosso, Michael A and Lanz, Hans J and Antman, Elliott M
Circulation, ISSN 0009-7322, 2015, Volume 131, Issue 1, pp. 82 - 90
Background-The oral factor Xa inhibitor edoxaban has demonstrated safety and efficacy in stroke prevention in patients with atrial fibrillation and in the... 
anticoagulants | thrombin | hemodynamics | pharmacology | CARDIAC & CARDIOVASCULAR SYSTEMS | SAFETY | RIVAROXABAN | RFVIIA | ANTIDOTE | DABIGATRAN | PHARMACOKINETICS | WARFARIN | PERIPHERAL VASCULAR DISEASE | AGENTS | HEALTHY-VOLUNTEERS | FACTOR XA INHIBITOR | Humans | Middle Aged | Prothrombin Time | Male | Thiazoles - administration & dosage | Hemorrhage - prevention & control | Thiazoles - therapeutic use | Thiazoles - adverse effects | Factor Xa Inhibitors - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Pyridines - adverse effects | Time Factors | Adult | Blood Coagulation Factors - pharmacology | Female | Pyridines - therapeutic use | Pyridines - administration & dosage | Double-Blind Method | Cross-Over Studies | Administration, Intravenous | Factor Xa Inhibitors - therapeutic use | Blood Coagulation - drug effects | Factor Xa Inhibitors - adverse effects | Adolescent | Biopsy, Needle - adverse effects | Dose-response relationship (Biochemistry) | Treatment outcome | Analysis | Atrial fibrillation | Drug therapy | Hemorrhage | Risk factors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Multi-modal contributions to detoxification of acute pharmacotoxicity by a triglyceride micro-emulsion
by Fettiplace, Michael R and Lis, Kinga and Ripper, Richard and Kowal, Katarzyna and Pichurko, Adrian and Vitello, Dominic and Rubinstein, Israel and Schwartz, David and Akpa, Belinda S and Weinberg, Guy
Journal of Controlled Release, ISSN 0168-3659, 01/2015, Volume 198, pp. 62 - 70
Triglyceride micro-emulsions such as Intralipid® have been used to reverse cardiac toxicity induced by a number of drugs but reservations about their... 
Local anesthetic | Biodetoxification | Lipid emulsion | Bupivacaine | Triglyceride | Antidote | ISOLATED RAT-HEART | MYOCARDIAL-FUNCTION | BUPIVACAINE TOXICITY | CHEMISTRY, MULTIDISCIPLINARY | INTRAVENOUS LIPID EMULSION | RECOVERY | RESCUE | SINK | LOCAL-ANESTHETICS | I-NA | PHARMACOLOGY & PHARMACY | CLOMIPRAMINE TOXICITY | Emulsions - therapeutic use | Cardiotoxins - toxicity | Bupivacaine - pharmacokinetics | Cardiotoxicity - physiopathology | Muscle, Skeletal - metabolism | Emulsions - pharmacology | Soybean Oil - pharmacology | Cardiotonic Agents - therapeutic use | Emulsions - administration & dosage | Cardiotoxicity - drug therapy | Myocardium - metabolism | Soybean Oil - administration & dosage | Triglycerides - therapeutic use | Triglycerides - pharmacology | Phospholipids - therapeutic use | Cardiotoxins - pharmacokinetics | Phospholipids - administration & dosage | Bupivacaine - toxicity | Cardiac Output - drug effects | Liver - metabolism | Rats | Soybean Oil - therapeutic use | Cardiotonic Agents - pharmacology | Phospholipids - pharmacology | Triglycerides - administration & dosage | Animals | Cardiotonic Agents - administration & dosage | Cardiotoxicity - metabolism | Models, Biological | Analysis | Triglycerides | Index Medicus | triglyceride | local anesthetic | bupivacaine | antidote | biodetoxification | pharmacotoxicity
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text 2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation
by Andrade, Jason G and Verma, Subodh and Verma, Atul and Mitchell, L. Brent and Parkash, Ratika and Leblanc, Kori and Atzema, Clare and Healey, Jeff S and Bell, Alan and Cairns, John and Connolly, Stuart and Cox, Jafna and Dorian, Paul and Gladstone, David and McMurtry, M. Sean and Nair, Girish M and Pilote, Louise and Sarrazin, Jean-Francois and Sharma, Mike and Skanes, Allan and Talajic, Mario and Tsang, Teresa and Wyse, D. George and Nattel, Stanley and Macle, Laurent and CCS Atrial Fibrillation Guidelines and CCS Atrial Fibrillation Guidelines Committee
Canadian Journal of Cardiology, ISSN 0828-282X, 11/2018, Volume 34, Issue 11, pp. 1371 - 1392
The Canadian Cardiovascular Society (CCS) Atrial Fibrillation Guidelines Committee provides periodic reviews of new data to produce focused updates that... 
CARDIAC & CARDIOVASCULAR SYSTEMS | DIRECT-CURRENT CARDIOVERSION | HEART-FAILURE | ACUTE MYOCARDIAL-INFARCTION | CATHETER ABLATION | ANTAGONIST ORAL ANTICOAGULANTS | EMERGENCY-DEPARTMENT PATIENTS | SPONTANEOUS ECHO CONTRAST | PULMONARY-VEIN ABLATION | ANTIARRHYTHMIC-DRUG THERAPY | ELECTRICAL CARDIOVERSION | Heart Failure - complications | Stroke - prevention & control | Echocardiography, Transesophageal | Comorbidity | Atrial Fibrillation - therapy | Humans | Risk Factors | Atrial Fibrillation - complications | Electric Countershock | Anticoagulants - therapeutic use | Catheter Ablation | Anti-Arrhythmia Agents - therapeutic use | Coronary Artery Disease - drug therapy | Coagulants - therapeutic use | Heart Failure - therapy | Hemorrhage - drug therapy | Stroke - etiology | Algorithms | Societies, Medical | Coronary Artery Disease - complications | Fibrinolytic Agents - therapeutic use | Hemorrhage - chemically induced | Drug Therapy, Combination | Antidotes - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants
by Weitz, Jeffrey I and Pollack, Charles V
Thrombosis and Haemostasis, ISSN 0340-6245, 2015, Volume 113, Issue 6, pp. 1113 - 1126
Summary Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used in the prevention and treatment of venous thromboembolism and in the... 
Review Article | Bleeding management | Bleeding profiles | Reversal agent | Non-vitamin K oral anticoagulant | Real-world data | DABIGATRAN ANTICOAGULATION | STROKE PREVENTION | HEMOSTATIC AGENTS | real-world data | reversal agent | RANDOMIZED EVALUATION | bleeding management | non-vitamin K oral anticoagulant | INTRACRANIAL HEMORRHAGE | ACTIVATED FACTOR-VII | PROTHROMBIN COMPLEX CONCENTRATE | PERIPHERAL VASCULAR DISEASE | NONVALVULAR ATRIAL-FIBRILLATION | HEMATOLOGY | ACUTE VENOUS THROMBOEMBOLISM | ELDERLY-PATIENTS | Perioperative Care | Recombinant Proteins - therapeutic use | Meta-Analysis as Topic | Postoperative Hemorrhage - prevention & control | Humans | Clinical Protocols | Warfarin - adverse effects | Postoperative Hemorrhage - chemically induced | Vulnerable Populations | Antithrombins - pharmacokinetics | Thrombophilia - etiology | Neoplasms - complications | Clinical Trials, Phase III as Topic | Blood Transfusion | Drug Design | Retrospective Studies | Thrombophilia - drug therapy | Antidotes - chemistry | Risk Assessment | Hemorrhage - therapy | Antithrombins - therapeutic use | Atrial Fibrillation - complications | Factor Xa Inhibitors - pharmacokinetics | Randomized Controlled Trials as Topic | Factor Xa Inhibitors - therapeutic use | Intracranial Hemorrhages - therapy | Hemostatic Techniques | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Intracranial Hemorrhages - chemically induced | Blood Coagulation Factors - therapeutic use | Kidney Failure, Chronic - complications | Aged | Disease Management | Hemorrhage - chemically induced | Antidotes - therapeutic use | Renal Dialysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text The Use of Antidotes for Calcium Gluconate Extravasation: An Experimental Study in Mice
by Pacheco Compaña, Francisco Javier and Míguez, José Midón and de Toro Santos, Francisco Javier and Centeno Cortés, Alberto and López San Martín, Patricia and Yebra-Pimentel Vidal, María Teresa and Mosquera Osés, Joaquín José
Plastic and Reconstructive Surgery, ISSN 0032-1052, 06/2018, Volume 142, Issue 3, pp. 699 - 707
BACKGROUNDCalcium Gluconate Extravasation is a process that can cause serious lesions, such as necrosis and calcification of the soft tissues. The aim of the... 
CALCINOSIS CUTIS | SURGERY | CALCIPHYLAXIS | THERAPY | INJURIES | NECROSIS | EFFICACY | UREMIC ARTERIOLOPATHY | CALCIFICATION | INTRAVENOUS-SODIUM THIOSULFATE | HYALURONIDASE | Thiosulfates - therapeutic use | Calcium Gluconate - adverse effects | Skin Diseases - chemically induced | Prospective Studies | Saline Solution - therapeutic use | Triamcinolone Acetonide - therapeutic use | Male | Treatment Outcome | Calcinosis - chemically induced | Skin Diseases - prevention & control | Animals | Calcinosis - prevention & control | Mice | Mice, Inbred BALB C | Antidotes - therapeutic use | Hyaluronoglucosaminidase - therapeutic use | Calcium gluconate | Usage | Physiological aspects | Calcification | Causes of | Health aspects | Sodium thiosulfate | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights